Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Calyptus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.
Brand Name : Cetrorelix Acetate-Generic
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Calyptus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved
Recipient : American Regent
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Launches a New Vial Presentation
Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Brand Name : ProvayBlue
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2022
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : American Regent
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
